2016 Astellas Transparency Disclosure Report
The EFPIA Disclosure Code requires all member companies to document and disclose certain Transfers of Value they make, directly or indirectly, to or for the benefit of, Healthcare Professionals (“HCPs”) or Healthcare Organisations (“HCOs”) (“Disclosures”).
The EFPIA Disclosure Code is implemented in Finland by the Pharma Industry Finland’s (PIF) Code of Ethics. Astellas discloses all Transfers of Value to HCPs and HCOs in accordance with its commitment to the EFPIA Disclosure Code and any applicable Finnish national code.
Astellas’ global vision is to be in the forefront of healthcare change by turning innovative science into value for patients.
Most of Astellas Finland’s financial support was focusing on education for Health Care Organizations and Health Care Providers in Nephrology, Oncology and Urology specialty areas during 2016.
The costs were mostly due to the travel and accommodation 37 % of the total costs (165 282.93 €). And also some honorarium for some lectures 12% of the total costs (54 228.66 €). Astellas Finland’s financial support for R&D was 80 475.98 €.
Astellas Finland provided support for congress education internationally. We also supported education for European and Nordic events organized by External Experts with a grant of Astellas Europe or Astellas Nordic.
Astellas Finland supported locally Nephrology, Oncology and Urology Associations to organize education events. And also hospitals to organize local educational events.